Market revenue in 2023 | USD 91.9 million |
Market revenue in 2030 | USD 147.8 million |
Growth rate | 7% (CAGR from 2023 to 2030) |
Largest segment | Small molecule |
Fastest growing segment | Large Molecule |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule, Large Molecule |
Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Small molecule was the largest segment with a revenue share of 63.55% in 2024. Horizon Databook has segmented the Sweden in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
Sweden has a strong biomedical research infrastructure, with several academic institutions, research centers, and hospitals. These institutions actively engage in research activities and foster collaborations with in vivo CROs to support preclinical and translational studies.
Furthermore, several technological advancements in healthcare and life sciences contribute to the country’s market growth. By leveraging state-of-the-art facilities, cutting-edge imaging technologies, and specialized equipment, CROs in the country are well-equipped to deliver exceptional in vivo research services of the highest quality.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account